应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00460 四环医药
未开盘 08-23 16:08:27
0.530
-0.010
-1.85%
最高
0.540
最低
0.530
成交量
265.30万
今开
0.530
昨收
0.540
日振幅
1.85%
总市值
49.40亿
流通市值
49.40亿
总股本
93.20亿
成交额
142.15万
换手率
0.03%
流通股本
93.20亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
四环医药(00460.HK)将于8月30日举行董事会会议以审批中期业绩
格隆汇资讯 · 08-20
四环医药(00460.HK)将于8月30日举行董事会会议以审批中期业绩
四环医药(00460)出现大手买入290万股,成交价$0.54,涉资156.6万
阿斯达克财经 · 08-20
四环医药(00460)出现大手买入290万股,成交价$0.54,涉资156.6万
四环医药(00460.HK):进击的惠升生物:两大国产首款胰岛素力作!重塑糖尿病治疗版图
格隆汇资讯 · 08-19
四环医药(00460.HK):进击的惠升生物:两大国产首款胰岛素力作!重塑糖尿病治疗版图
医美概念股全线上扬 康哲药业(00867)涨9.47% 机构指医美类差异化上游厂商抢占市场能力更强
金吾财讯 · 08-16
医美概念股全线上扬 康哲药业(00867)涨9.47% 机构指医美类差异化上游厂商抢占市场能力更强
港股异动 | 四环医药(00460)涨近4% 治疗糖尿病药物获国家药监局批准上市
智通财经 · 08-16
港股异动 | 四环医药(00460)涨近4% 治疗糖尿病药物获国家药监局批准上市
四环医药08月14日遭主力抛售93万元 环比增加116.28%
自选股智能写手 · 08-14
四环医药08月14日遭主力抛售93万元 环比增加116.28%
四环医药(00460):惠升生物研发的德谷胰岛素注射液“惠优达®”获国家药监局批准上市
智通财经 · 08-14
四环医药(00460):惠升生物研发的德谷胰岛素注射液“惠优达®”获国家药监局批准上市
【港股通】四环医药(00460):惠升生物研发的德谷胰岛素注射液惠优达获国家药监局批准上市
金吾财讯 · 08-14
【港股通】四环医药(00460):惠升生物研发的德谷胰岛素注射液惠优达获国家药监局批准上市
四环医药(00460.HK)治疗糖尿病药物获国家药监局批准上市
阿斯达克财经 · 08-14
四环医药(00460.HK)治疗糖尿病药物获国家药监局批准上市
国产德谷门冬双胰岛素首发!惠升生物携多重磅药争做糖尿病药企出海一哥
格隆汇 · 08-12
国产德谷门冬双胰岛素首发!惠升生物携多重磅药争做糖尿病药企出海一哥
四环医药08月09日遭主力抛售154万元 环比增加196.15%
自选股智能写手 · 08-09
四环医药08月09日遭主力抛售154万元 环比增加196.15%
南向资金8月6日净买入四环医药56.80万股 连续3日增持
自选股智能写手 · 08-07
南向资金8月6日净买入四环医药56.80万股 连续3日增持
四环医药涨6% 旗下胰岛素注射液获国家药监局批准上市
智通财经 · 08-06
四环医药涨6% 旗下胰岛素注射液获国家药监局批准上市
港股异动丨四环医药涨6% 旗下胰岛素注射液获国家药监局批准上市四环医药(0460.HK)现涨6%报0.53港元,最新市值49.
格隆汇 · 08-06
港股异动丨四环医药涨6% 旗下胰岛素注射液获国家药监局批准上市四环医药(0460.HK)现涨6%报0.53港元,最新市值49.
【港股异动 | 四环医药(00460.HK)午后升6% 旗下胰岛素注射液获国家药监局批准上市】智通财经APP获悉,四环医药(00460.
智通财经 · 08-06
【港股异动 | 四环医药(00460.HK)午后升6% 旗下胰岛素注射液获国家药监局批准上市】智通财经APP获悉,四环医药(00460.
港股异动 | 四环医药(00460)午后升6% 旗下胰岛素注射液获国家药监局批准上市
智通财经网 · 08-06
港股异动 | 四环医药(00460)午后升6% 旗下胰岛素注射液获国家药监局批准上市
【港股通】四环医药(00460):惠升生物研发的德谷门冬双胰岛素注射液惠优加获国家药监局批准上市
金吾财讯 · 08-06
【港股通】四环医药(00460):惠升生物研发的德谷门冬双胰岛素注射液惠优加获国家药监局批准上市
四环医药(00460):惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市
智通财经网 · 08-06
四环医药(00460):惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市
【四环医药(00460.HK):惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯,四环医药(00460.
智通财经 · 08-06
【四环医药(00460.HK):惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯,四环医药(00460.
四环医药(00460.HK)旗下胰岛素注射液获批上市
阿斯达克财经 · 08-06
四环医药(00460.HK)旗下胰岛素注射液获批上市
暂无数据
公司概况
公司名称:
四环医药
所属市场:
SEHK
上市日期:
--
主营业务:
四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事研发、制造及销售药品。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其心脑血管产品包括克林澳、安捷利及欧迪美等。其非心脑血管产品包括仁澳、甲硝唑及罗沙替丁等。
发行价格:
--
{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":0.53,"timestamp":1724400507025,"preClose":0.54,"halted":0,"volume":2653000,"delay":0,"floatShares":9319999206,"shares":9319999206,"eps":-0.006359995,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.01,"latestTime":"08-23 16:08:27","open":0.53,"high":0.54,"low":0.53,"amount":1421510,"amplitude":0.018519,"askPrice":0.54,"askSize":4531000,"bidPrice":0.53,"bidSize":3467000,"shortable":3,"etf":0,"ttmEps":-0.006359994855245311,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":0.54,"dividendRate":0.065085,"openAndCloseTimeList":[[1724376600000,1724385600000],[1724389200000,1724400000000]],"volumeRatio":0.6285836136893195,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460/tweets","defaultTab":"tweets","newsList":[{"id":"2460022438","title":"四环医药(00460.HK)将于8月30日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2460022438","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460022438?lang=zh_cn&edition=full","pubTime":"2024-08-20 17:01","pubTimestamp":1724144487,"startTime":"0","endTime":"0","summary":"格隆汇8月20日丨四环医药(00460.HK)公布,公司将于2024年8月30日举行董事会会议,藉以考虑及批准公司及其附属公司截至2024年6月30日止六个月中期业绩及其发布,并考虑派付中期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408201701379f3d4a6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408201701379f3d4a6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","00460","BK1600","BK1515","BK1191"],"gpt_icon":0},{"id":"2460019587","title":"四环医药(00460)出现大手买入290万股,成交价$0.54,涉资156.6万","url":"https://stock-news.laohu8.com/highlight/detail?id=2460019587","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460019587?lang=zh_cn&edition=full","pubTime":"2024-08-20 10:13","pubTimestamp":1724119980,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在上午10:13出现大手买入,成交量为290万,成交价为港币$0.54,涉资156.6万。至目前为止,股价跌1.852%,今日最高价为$0.54,而最低价为$0.53,总成交量为362.5万股,总成交金额港币$195.659万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2408203471/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","00460","BK1515","BK1600","BK1593"],"gpt_icon":0},{"id":"2460725708","title":"四环医药(00460.HK):进击的惠升生物:两大国产首款胰岛素力作!重塑糖尿病治疗版图","url":"https://stock-news.laohu8.com/highlight/detail?id=2460725708","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460725708?lang=zh_cn&edition=full","pubTime":"2024-08-19 08:45","pubTimestamp":1724028329,"startTime":"0","endTime":"0","summary":"在不到十天的时间里,两款“国产首个”胰岛素的获批上市,可以说重塑了国内胰岛素的市场格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081908454195a496e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081908454195a496e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","BK1515","00460","BK1593","BK1191"],"gpt_icon":0},{"id":"2459250009","title":"医美概念股全线上扬 康哲药业(00867)涨9.47% 机构指医美类差异化上游厂商抢占市场能力更强","url":"https://stock-news.laohu8.com/highlight/detail?id=2459250009","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459250009?lang=zh_cn&edition=full","pubTime":"2024-08-16 14:26","pubTimestamp":1723789603,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股全线上扬,康哲药业(00867)涨9.47%,现代牙科(03600)涨4.93%,四环医药(00460)涨3.85%,医思健康(02138)涨2.86%,复星医药(02196)涨2.6%,瑞尔集团(06639)涨2.27%,昊海生物科技(06826)涨1.95%。开源证券研报指出,建议关注医美、化妆品行业的投资机会。医美类差异化上游厂商抢占市场能力更强,长期看“渗透率+国产化率+合规化程度”多维提升逻辑未变;化妆品行业温和复苏,机会与挑战并存,把握渠道、成分、品类等细分结构性机会且综合竞争力强劲的国货美妆品牌有望在变化中抢占市场。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/OWNjYzkwNTM4YzEwMTc4NjgyODQzNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWNjYzkwNTM4YzEwMTc4NjgyODQzNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942461","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","SG9999004220.SGD","BK1219","BK1593","06826","BK1100","06639","02138","BK1215","LU2488822045.USD","00460","BK1583","BK1600","BK1161","SG9999015978.USD","00867","BK1515","SG9999015945.SGD","BK1191","BK1511","SG9999015952.SGD","02196","03600"],"gpt_icon":0},{"id":"2459255529","title":"港股异动 | 四环医药(00460)涨近4% 治疗糖尿病药物获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2459255529","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459255529?lang=zh_cn&edition=full","pubTime":"2024-08-16 11:45","pubTimestamp":1723779946,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,四环医药(00460)涨近4%,截至发稿,涨3.85%,报0.54港元,成交额120.65万港元。消息面上,四环医药近日公布,旗下非全资附属公司惠升生物研发的德谷胰岛素注射液(商品名:惠优达®,“该产品”)已获国家药监局批准上市,用于治疗成人2型糖尿病。该产品是继原研产品诺和达®后国产首个获批上市的德谷胰岛素注射液生物类似药。值得一提的是,惠升生物的德谷门冬双胰岛素注射液生物类似药(商品名:惠优加)也在本月获批上市,用于治疗成人2型糖尿病。产品未来上市后将为集团和惠升生物的业绩和增长带来巨大新动能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1515","BK1191","00460","BK1600"],"gpt_icon":0},{"id":"2459145404","title":"四环医药08月14日遭主力抛售93万元 环比增加116.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459145404","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459145404?lang=zh_cn&edition=full","pubTime":"2024-08-14 16:15","pubTimestamp":1723623331,"startTime":"0","endTime":"0","summary":"08月14日,四环医药股价收平报0.53元,成交金额452万元,换手率0.09%,振幅3.77%,量比2.23。四环医药今日主力资金净流出93万元,上一交易日主力净流出43万元,今日环比增加116.28%。该股近5个交易日下跌3.70%,主力资金累计净流出340万元;近20日主力资金累计净流出553万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408141615469597b158&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408141615469597b158&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2459019478","title":"四环医药(00460):惠升生物研发的德谷胰岛素注射液“惠优达®”获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2459019478","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459019478?lang=zh_cn&edition=full","pubTime":"2024-08-14 12:23","pubTimestamp":1723609411,"startTime":"0","endTime":"0","summary":"智通财经APP讯,四环医药 发布公告,集团旗下非全资附属公司惠升生物制药股份有限公司研发的德谷胰岛素注射液已获中华人民共和国(中国)国家药品监督管理局批准上市,用于治疗成人2型糖尿病。该产品是继原研产品诺和达后国产首个获批上市的德谷胰岛素注射液生物类似药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1163872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00460","BK1515","BK1600","BK1593"],"gpt_icon":0},{"id":"2459192194","title":"【港股通】四环医药(00460):惠升生物研发的德谷胰岛素注射液惠优达获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2459192194","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459192194?lang=zh_cn&edition=full","pubTime":"2024-08-14 12:16","pubTimestamp":1723608963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 四环医药(00460)公布,旗下非全资附属公司惠升生物)研发的德谷胰岛素注射液(商品名:惠优达)已获中国国家药监局)批准上市,用于治疗成人2型糖尿病。该产品是继原研产品诺和达后国产首个获批上市的德谷胰岛素注射液生物类似药。德谷胰岛素是新一代长效基础胰岛素类似物,为国家医保目录乙类药物,具有独特的分子结构及长效作用机制,优异的降糖效果,并具有控制血糖浓度平稳、效果持久、低血糖风险低、安全性高等特点。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210510/ZGJjYTkxOGYyMGNlOTUwNjQ0NzUyMDkw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210510/ZGJjYTkxOGYyMGNlOTUwNjQ0NzUyMDkw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942260","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","YANG","BK1191","00460","BK1515","BK1600","HSCEI","BK1593"],"gpt_icon":1},{"id":"2459819476","title":"四环医药(00460.HK)治疗糖尿病药物获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2459819476","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459819476?lang=zh_cn&edition=full","pubTime":"2024-08-14 12:13","pubTimestamp":1723608780,"startTime":"0","endTime":"0","summary":"四环医药公布,旗下非全资附属惠升生物制药股份研发的德谷胰岛素注射液,已获中国国家药品监督管理局批准上市,用于治疗成人2型糖尿病。据悉,德谷胰岛素的半衰期长达25小时,持续作用时间约42小时,是第一种使糖尿病患者可在一天中任意时间注射的长效胰岛素,注射时间更为灵活,患者依从性更高。另外,使用德谷胰岛素的2型糖尿病患者低血糖发生风险显著降低,尤其是夜间重度低血糖发生率较甘精胰岛素显著减少53%。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1371475&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00460","BK1191","BK1600","BK1515","BK1593"],"gpt_icon":0},{"id":"2458610990","title":"国产德谷门冬双胰岛素首发!惠升生物携多重磅药争做糖尿病药企出海一哥","url":"https://stock-news.laohu8.com/highlight/detail?id=2458610990","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458610990?lang=zh_cn&edition=full","pubTime":"2024-08-12 08:51","pubTimestamp":1723423879,"startTime":"0","endTime":"0","summary":"国产首个获批上市的德谷门冬双胰岛素注射液生物类似药","market":"sg","thumbnail":"https://img7.gelonghui.com/column/6.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/6.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/917445","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1515","BK1593","00460","BK1191","BK1600"],"gpt_icon":0},{"id":"2458558207","title":"四环医药08月09日遭主力抛售154万元 环比增加196.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458558207","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458558207?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:15","pubTimestamp":1723191305,"startTime":"0","endTime":"0","summary":"08月09日, 四环医药股价跌1.85%,报收0.53元,成交金额299万元,换手率0.06%,振幅3.70%,量比0.60。四环医药今日主力资金净流出154万元,上一交易日主力净流出52万元,今日环比增加196.15%。该股近5个交易日上涨1.92%,主力资金累计净流入42万元;近20日主力资金累计净流出360万元,其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408091615139f1cf5ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408091615139f1cf5ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","00460","BK1191","BK1515","BK1593"],"gpt_icon":0},{"id":"2457831403","title":"南向资金8月6日净买入四环医药56.80万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2457831403","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457831403?lang=zh_cn&edition=full","pubTime":"2024-08-07 09:31","pubTimestamp":1722994280,"startTime":"0","endTime":"0","summary":"8月6日, 南向资金增持四环医药56.80万股,连续3日增持。截止当日收盘,港股通共持有四环医药82064.00万股,占流通股8.78%。港股通增持金额前五个股分别为小米集团-W、建设银行、腾讯控股、药明生物、中国移动。四环医药近5个交易日上涨1.92%,港股通累计减持11.60万股;近20个交易日下跌1.85%,港股通累计减持1633.30万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408070942589f15a83d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408070942589f15a83d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","BK1191","BK1600","00460"],"gpt_icon":0},{"id":"2457093885","title":"四环医药涨6% 旗下胰岛素注射液获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2457093885","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457093885?lang=zh_cn&edition=full","pubTime":"2024-08-06 15:10","pubTimestamp":1722928237,"startTime":"0","endTime":"0","summary":"四环医药近日宣布,集团旗下非全资附属公司惠升生物制药股份有限公司研发的德谷门冬双胰岛素注射液已获中国国家药监局批准上市,用于治疗成人2型糖尿病。是继原研诺和诺德后国产首个获批上市的德谷门冬双胰岛素注射液生物类似药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061514269f12f446&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061514269f12f446&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","00460","BK1600","BK1515","BK1191"],"gpt_icon":0},{"id":"2457064742","title":"港股异动丨四环医药涨6% 旗下胰岛素注射液获国家药监局批准上市四环医药(0460.HK)现涨6%报0.53港元,最新市值49.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457064742","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457064742?lang=zh_cn&edition=full","pubTime":"2024-08-06 14:30","pubTimestamp":1722925809,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2457606674","title":"【港股异动 | 四环医药(00460.HK)午后升6% 旗下胰岛素注射液获国家药监局批准上市】智通财经APP获悉,四环医药(00460.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457606674","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457606674?lang=zh_cn&edition=full","pubTime":"2024-08-06 13:41","pubTimestamp":1722922890,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1515","00460","BK1191","BK1600"],"gpt_icon":0},{"id":"2457066757","title":"港股异动 | 四环医药(00460)午后升6% 旗下胰岛素注射液获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2457066757","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457066757?lang=zh_cn&edition=full","pubTime":"2024-08-06 13:41","pubTimestamp":1722922890,"startTime":"0","endTime":"0","summary":"四环医药(00460)午后升6%,截至发稿,涨6%,报0.53港元,成交额600.53万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20240806/20240806134213_80342.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240806/20240806134213_80342.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1593","BK1191","00460","BK1515","BK1600"],"gpt_icon":0},{"id":"2457503870","title":"【港股通】四环医药(00460):惠升生物研发的德谷门冬双胰岛素注射液惠优加获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2457503870","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457503870?lang=zh_cn&edition=full","pubTime":"2024-08-06 12:14","pubTimestamp":1722917696,"startTime":"0","endTime":"0","summary":"金吾财讯 | 四环医药(00460)公布,集团旗下非全资附属公司惠升生物研发的德谷门冬双胰岛素注射液(商品名:惠优加)已获中国国家药监局批准上市,用于治疗成人2型糖尿病。是继原研诺和诺德后国产首个获批上市的德谷门冬双胰岛素注射液生物类似药。德谷门冬双胰岛素作为新一代胰岛素制剂,具有控制血糖更优,糖化血红素达标率更高,低血糖风险更小的优点。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/MzBjNmFjYTg0ZGViYjVhMGFmODhkMDhhN2E5MzY4MTQyOTQ2MzQ2MjU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MzBjNmFjYTg0ZGViYjVhMGFmODhkMDhhN2E5MzY4MTQyOTQ2MzQ2MjU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1941735","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","00460","BK1600","BK1515","HSCEI","BK1191","YANG","HSTECH"],"gpt_icon":1},{"id":"2457653057","title":"四环医药(00460):惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2457653057","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457653057?lang=zh_cn&edition=full","pubTime":"2024-08-06 12:04","pubTimestamp":1722917096,"startTime":"0","endTime":"0","summary":"四环医药(00460)公布,该集团旗下非全资附属公司惠升生物制药股份有限公司研发的...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240806/20240806120639_30757.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240806/20240806120639_30757.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00460","BK1593","BK1600","BK1515","BK1191"],"gpt_icon":0},{"id":"2457405769","title":"【四环医药(00460.HK):惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯,四环医药(00460.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457405769","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457405769?lang=zh_cn&edition=full","pubTime":"2024-08-06 12:04","pubTimestamp":1722917096,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LU1093756325.SGD","BK1515","BK1600","BK4007","IE00BKVL7J92.USD","BK1191","IE00BZ1G4Q59.USD","BK4585","NVO","LU0154236417.USD","BK4532","BK1593","LU1093756168.USD","00460"],"gpt_icon":0},{"id":"2457576960","title":"四环医药(00460.HK)旗下胰岛素注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2457576960","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457576960?lang=zh_cn&edition=full","pubTime":"2024-08-06 12:03","pubTimestamp":1722916980,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK) 公布,旗下非全资附属惠升生物研发的德谷门冬双胰岛素注射液(商品名为惠优加)已获国家药监局批准上市,用于治疗成人2型糖尿病。是继原研诺和诺德后国产首个获批上市的德谷门冬双胰岛素注射液生物类似药。德谷门冬双胰岛素作为新一代胰岛素制剂,具有控制血糖更优,糖化血红素达标率更高,低血糖风险更小的优点。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-05 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220413154450154_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220413154450154_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1369217/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1600","BK1191","00460","BK1515","BK1593"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":-0.0185},{"period":"1month","weight":-0.0185},{"period":"3month","weight":-0.0702},{"period":"6month","weight":-0.0862},{"period":"1year","weight":-0.197},{"period":"ytd","weight":-0.1846}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事研发、制造及销售药品。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其心脑血管产品包括克林澳、安捷利及欧迪美等。其非心脑血管产品包括仁澳、甲硝唑及罗沙替丁等。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.124332},{"month":2,"riseRate":0.571429,"avgChangeRate":0.002088},{"month":3,"riseRate":0.357143,"avgChangeRate":-0.025475},{"month":4,"riseRate":0.538462,"avgChangeRate":0.029528},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.005604},{"month":6,"riseRate":0.538462,"avgChangeRate":-0.006553},{"month":7,"riseRate":0.538462,"avgChangeRate":-0.00596},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.025779},{"month":9,"riseRate":0.083333,"avgChangeRate":-0.082523},{"month":10,"riseRate":0.583333,"avgChangeRate":0.030986},{"month":11,"riseRate":0.538462,"avgChangeRate":0.020616},{"month":12,"riseRate":0.461538,"avgChangeRate":-0.01024}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}